Lantus market outlook points to biosimilars, digital diabetes tools and aging populations

The Business Research Company says the global Lantus market is set for growth through 2035, driven by rising diabetes rates, older populations and demand for steadier, more affordable insulin options. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Lantus is a widely used long-acting insulin, so changes in its market can affect diabetes treatment access, affordability and daily disease management. - The market outlook points to stronger demand for basal insulin therapies as diabetes cases rise and care shifts toward more personalized, digitally supported treatment. - Biosimilar competition could pressure pricing and reshape how patients and providers choose long-acting insulin products.

What happened: - The Business Research Company published its Lantus Global Market Report 2026, covering market size, trends and a forecast through 2035. - The report says the Lantus market has grown on the back of rising diabetes prevalence, insulin formulation advances, wider use of basal insulin therapies, more outpatient diabetes care and better adherence tools. - The report says future growth will be driven by biosimilar competition, personalized insulin regimens, digital diabetes tools, demand for lower-cost insulin and new delivery systems. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Lantus, chemically known as insulin glargine, is a long-acting insulin designed to help people with diabetes control blood sugar over a 24-hour period. - The insulin releases steadily, which helps mimic the body’s natural insulin production. - Steadier release reduces glucose swings and supports more stable blood sugar control. - The report highlights growing acceptance of long-acting insulin analogues. - The report also points to increased use of once-daily dosing, comprehensive diabetes care programs and pre-filled insulin delivery devices. - Rising diabetes prevalence is the main demand driver. - Contributing factors include sedentary lifestyles, poor diets, obesity, genetic predisposition and an aging population. - In March 2024, the UK Office for Health Improvement and Disparities said the share of people with type 1 diabetes in England receiving comprehensive care rose to 43.8% in 2023 from 35.2% in 2022. - The report says that improvement reflects better diabetes management and supports market growth. - The geriatric population is another key driver. - Older adults face higher diabetes risk and more complications from hyperglycemia. - In July 2024, the UK Parliament’s House of Commons Library said the UK had 12.7 million people aged 65 or older in 2022, or about 19% of the population. - The same source projects that number will rise to 22.1 million, or 27%, by 2072.

Between the lines: - The report points to a market that is moving in two directions at once: toward more advanced diabetes care and toward lower-cost competition. - Biosimilars and affordability pressure suggest pricing will become a bigger issue even as demand expands. - The emphasis on once-daily dosing and delivery devices suggests convenience remains a major buying factor for patients and providers.

What's next: - The report expects growth to continue through 2035 as diabetes prevalence rises and healthcare systems expand access to treatment. - Asia-Pacific’s growth should be supported by more diabetes cases, broader healthcare access and greater awareness of diabetes management. - The report’s new 2026 features include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables. - The report also says it covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The bottom line: - Lantus remains a core diabetes therapy, but its market is heading into a more competitive and cost-sensitive phase as biosimilars, digital tools and aging populations reshape demand.